Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- Drug: Standard maintenance for squamous NSCLC
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 999
- Registration Number
- NCT02117167
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Paoli Calmettes, Marseille, France
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 10
- Registration Number
- NCT02109250
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UZ Brussel, Brussels, Belgium
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT02015065
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study
- Conditions
- Gastrointestinal Cancers
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT02013089
- Locations
- 🇨🇳
Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
- Conditions
- Symptomatic, Aggressive, Sporadic, Unresectable, LocallyAdvanced/Metastatic Medullary Thyroid Cancer (MTC)
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 31
- Registration Number
- NCT01945762
- Locations
- 🇧🇪
investigational Site Belgium, Belgium, Belgium
🇫🇷investigational Site France, France, France
🇩🇪investigational Site Germany, Germany, Germany
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
- Conditions
- ParagangliomaPhaeochromocytoma
- Interventions
- Radiation: 131I-mIBG
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- University College, London
- Registration Number
- NCT01941849
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, London, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Ronald Weigel
- Target Recruit Count
- 12
- Registration Number
- NCT01934335
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 238
- Registration Number
- NCT01876784
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
🇺🇸Washington University, Saint Louis, Missouri, United States
Vandetanib in Advanced NSCLC With RET Rearrangement
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT01823068
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
- Conditions
- Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 14
- Registration Number
- NCT01661179
- Locations
- 🇯🇵
Research Site, Shinjuku-ku, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.